Pulse BiosciencesPLSE
Market Cap: $1.1B
About: Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Employees: 56
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
61% more call options, than puts
Call options by funds: $2.15M | Put options by funds: $1.33M
41% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 17
29% more capital invested
Capital invested by funds: $41.7M [Q1] → $54.1M (+$12.3M) [Q2]
0.03% more ownership
Funds ownership: 8.71% [Q1] → 8.75% (+0.03%) [Q2]
7% less funds holding
Funds holding: 61 [Q1] → 57 (-4) [Q2]
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Research analyst outlook
We haven’t received any recent analyst ratings for PLSE.